区域淋巴结清扫对比扩大淋巴结清扫治疗肝门部胆管癌(Relay-HC试验):一项前瞻性多中心随机对照试验的研究方案
Relay-HC试验为前瞻性多中心随机对照试验,计划在中国15家三级医院纳入734例可切除的肝门部胆管癌患者,按1:1随机分配至区域淋巴结清扫组或扩大淋巴结清扫组,主要目的为比较两种清扫方式后的总生存期。
要点
- 扩大淋巴结清扫对肝门部胆管癌的预后获益与安全性尚不确定,现有证据多为回顾性且不充分。
- Relay-HC试验为前瞻性多中心随机对照试验,计划纳入734例可切除肝门部胆管癌患者。
- 患者按1:1随机分配至区域淋巴结清扫组或扩大淋巴结清扫组,主要终点为总生存期。
核心结论
- Relay-HC试验旨在探讨扩大淋巴结清扫对肝门部胆管癌的预后获益与安全性,此前从未在前瞻性随机对照临床试验中研究过。
研究设计与样本
- Relay-HC试验为前瞻性、多中心、随机对照试验,在中国15家三级医院纳入734例可切除的肝门部胆管癌患者,按1:1随机分配至区域淋巴结清扫组或扩大淋巴结清扫组。
关键数值与推荐
- 主要目的为确定两种清扫方式后的总生存期。
- 次要目的包括评估围手术期死亡率、术后并发症和无病生存期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic benefits and safety of extended lymphadenectomy for hilar cholangiocarcinoma remain uncertain. The available evidence is still insufficient concerning its retrospective aspect. The aim of this study is to explore the clinical effect and safety of extended lymphadenectomy compared to regional lymphadenectomy in patients with hilar cholangiocarcinoma. METHODS: The Relay-HC trial is a prospective, multicenter, and randomized controlled trial. Seven hundred and thirty-four eligible patients with resectable perihilar cholangiocarcinoma across 15 tertiary hospitals in China will be randomly assigned (1:1) to receive either regional lymphadenectomy or extended lymphadenectomy. The primary objective is to determine the overall survival after the two approaches. Secondary objectives of the study include the evaluation of perioperative mortality, postoperative complication, and disease-free survival. This study has been approved by the ethics committee of each participating hospital. DISCUSSION: The Relay-HC trial is designed to investigate the prognostic benefits and safety of expanded lymphadenectomy for hilar cholangiocarcinoma. Currently, it has never been investigated in a prospective randomized controlled clinical trial. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR), ChiCTR1800015688 . Registered on 15 April 2018.
引用
- He M, Xu X, Feng H, et al. Regional lymphadenectomy vs. extended lymphadenectomy for hilar cholangiocarcinoma (Relay-HC trial): study protocol for a prospective, multicenter, randomized controlled trial. Trials. 2019. PMID: 31443731. doi:10.1186/s13063-019-3605-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。